Clinical Efficacy Evaluation of Sirolimus in Congenital Hyperinsulinism

BACKGROUND: Congenital hyperinsulinism (CHI) is a rare and life-threatening genetic disorder. Sirolimus as a mammalian target of rapamycin inhibitor may be helpful in patients with CHI who do not respond well to other treatments including diazoxide and octreotide. However, the safety and efficacy of...

Descripción completa

Detalles Bibliográficos
Autores principales: Hashemian, Somayyeh, Jafarzadeh Esfehani, Reza, Karimdadi, Siroos, Vakili, Rahim, Zamanfar, Daniel, Sahebkar, Amirhossein
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7396056/
https://www.ncbi.nlm.nih.gov/pubmed/32774365
http://dx.doi.org/10.1155/2020/7250406

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7396056/
https://www.ncbi.nlm.nih.gov/pubmed/32774365
http://dx.doi.org/10.1155/2020/7250406

Ejemplares similares